Novartis, CH0012005267

Novartis stock fell 1.46 percent on October 2 after Abogen deal

Published on 10/04/2026 at 18:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis stock was last at CHF 116.34 on October 2, with a 52-week range of CHF 97.05 to CHF 132.68. Q2 revenue reached CHF 14.16 billion.

Forscherin in weißem Kittel pipettiert in Reagenzglas im sterilen Pharmalabor — Novartis AG CH0012005267 – Forscherin pipettiert präzise in steriler Pharmalaborumgebung mit Reagenzgläsern, Illustration mit AI erstellt.

Novartis stock (ISIN CH0012005267) fell 1.46 percent on October 2 to a last price of CHF 116.34 on SIX. The move followed a licensing agreement with Abogen Biosciences valued at up to USD 7.8 billion, giving Novartis rights to an experimental autoimmune treatment and options on additional therapies.

Abogen deal adds pipeline access

As Reuters reported on October 2, Abogen will receive USD 575 million upfront and could earn up to USD 7.2 billion in development, regulatory and commercial milestones. The agreement gives Novartis exclusive rights to ABO2203, an mRNA-based therapy designed to target disease-causing B cells.

CNBC reported on October 2 that the deal also includes an exclusive option on other assets developed through Abogen's RNA platform. For Novartis, the structure limits the initial payment while leaving most of the potential consideration dependent on development and approval milestones.

Q2 figures show lower profit

Novartis reported CHF 14.16 billion in Q2 2026 revenue and CHF 3.21 billion in net profit, according to Markets Insider. The prior-year quarter delivered CHF 14.84 billion in revenue and CHF 4.04 billion in net profit, making the latest result a year-over-year decline on both measures.

The same Markets Insider report said Goldman Sachs maintained a Sell rating on October 1 with a CHF 110.00 price target. That target sits below the October 2 last price, keeping pipeline execution and late-stage development outcomes central to the stock story.

Stock remains below yearly high

Novartis was last at CHF 116.34 on SIX at 5:30 p.m. CEST on October 2, while the session range ran from CHF 116.20 to CHF 118.64. The 52-week range was CHF 97.05 to CHF 132.68, placing the share CHF 16.34 below its yearly high.

Market capitalization stood at CHF 221.1 billion on October 2, with trading volume of 2,595,569 shares. Novartis has scheduled its Q3 2026 financial results for October 27, 2026, according to its Novartis investor calendar.

Novartis stock stays in range

Novartis stock combines a CHF 221.1 billion market value with a 1.46 percent decline on October 2 and a pipeline deal whose maximum value is USD 7.8 billion. The next valuation test is the October 27 Q3 report, when investors can compare new pipeline spending with operating performance.